Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,789 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Eating Disorders, Binge Eating, Purging (Eating Disorders), Bulimia Nervosa, Anorexia Nervosa, Atypical
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 13 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality
Interventions: Pancrelipase, Placebo Oral Capsule; Drug
Lead sponsor: Massimo Raimondo, M.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Glucose Metabolism Disorders
Interventions: NMN supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Autism, Autistic Disorder
Interventions: Gluten- and casein-free diet, Placebo controlled diet; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 30 Months to 54 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Knee Osteoarthritis, Obese, Depression
Interventions: Fisetin, GetHealthy-OA mind-body program, Placebo oral capsule, Health education booklet; Drug · Behavioral
Lead sponsor: Cale Andrew Jacobs, PhD; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: D-serine, placebo, Sensory Based remediation paradigm; Drug · Behavioral
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
Interventions: Erchonia® EVRL™, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • West Covina, California • Dunedin, Florida + 1 more

Conditions: Postoperative Nausea and Vomiting
Interventions: Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: Up to 16 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Repetitive transcranial magnetic stimulation, Sham; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Left Rostromedial Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Dorsolateral Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Primary Somatosensory Cortex - Accelerated Intermittent Theta Burst
Interventions: Accelerated Intermittent Theta Burst Transcranial Magnetic Stimulation; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions: Collagenase Clostridium Histolyticum, Placebo; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Santa Monica, California • Coral Gables, Florida + 7 more

Conditions: Quality of Life, Health, Subjective
Interventions: RS blend, Placebo; Dietary Supplement · Other
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Gig Harbor, Washington

Conditions: Cannabis Use, Pain, Acute
Interventions: Cannabis; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Anterior Cruciate Ligament Injuries, Post-Traumatic Osteoarthritis of Knee, Bone Marrow Aspirate Concentrate, ACL Injury
Interventions: Concentrated Bone Marrow Aspirate Injection, Sham Incision, Revision Anterior Cruciate Ligament Reconstruction; Biological · Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: COVID-19
Interventions: Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Photoparoxysmal Abnormalities, Epilepsy, Seizures
Interventions: Mozart K448, Beethoven's Für Elise, No music exposure; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 5 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Stroke, Stroke Sequelae, Hemiparesis;Poststroke/CVA
Interventions: StrokeWear Motor and Behavioral Intervention, Usual Care; Combination Product · Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leiomyoma
Interventions: EGCG ( Green Tea extract), Brown rice pills; Dietary Supplement
Lead sponsor: Meharry Medical College; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Microbiome
Interventions: strawberry powder, placebo powder; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fragile X Syndrome
Interventions: Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fibromyalgia
Interventions: RINCE; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions: Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 8 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Opioid-Use Disorder
Interventions: Placebo, TRV734, Oxycodone; Other · Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Naltrexone Neuroimaging in Teens With Eating Disorders

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

Diet and Behavior in Young Children With Autism

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation

Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

Resistant Starch Blend Gastrointestinal Impact

Eye Tracking as a Biomarker of Cannabis Effects

Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction

Impact of Lp299v on Vascular Function in Patients With PASC

Prevention of Photoparoxysmal Abnormalities by Mozart K448

Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors

Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids

Effect of Strawberry Consumption on the Microbiome

Neurophysiological and Acute Pharmacological Studies in FXS Patients

A Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - University of Michigan

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD